Entering text into the input field will update the search result below

Horizon Therapeutics Public Limited Company (HZNP) CEO Tim Walbert on Q1 2020 Results - Earnings Call Transcript

SA Transcripts profile picture
SA Transcripts

Horizon Therapeutics Public Limited Company (NASDAQ:HZNP) Q1 2020 Earnings Conference Call May 6, 2020 8:00 AM ET

Company Participants

Tina Ventura - Senior Vice President, Investor Relations

Tim Walbert - Chairman, President & Chief Executive Officer

Liz Thompson - Group Vice President, Clinical Development & External Search

Paul Hoelscher - Executive Vice President & Chief Financial Officer

Vikram Karnani - Executive Vice President, Chief Commercial Officer

Andy Pasternak - Executive Vice President, Chief Business Officer

Conference Call Participants

Jason Gerberry - Bank of America

David Steinberg - Jefferies

Annabel Samimy - Stifel

David Amsellem - Piper Sandler

Gary Nachman - BMO Capital Markets

Ken Cacciatore - Cowen and Company

David Risinger - Morgan Stanley

Dana Flanders - Guggenheim


Good morning and thank you for standing by. Welcome to the Horizon Therapeutics plc First Quarter 2020 Earnings Conference Call. At this time, all participant lines are in a listen-only mode. After the speakers' presentation, there will be a question-and-answer session. As a reminder, today's conference is being recorded. [Operator Instructions]

I would now like to introduce, Ms. Tina Ventura, Senior Vice President of Investor Relations.

Tina Ventura

Thank you, Chris. Good morning everyone and thank you for joining us. On the call with me today are Tim Walbert, Chairman President and Chief Executive Officer; Liz Thompson, Group Vice President Clinical Development and External Search; Paul Hoelscher, Executive Vice President, Chief Financial Officer; Vikram Karnani, Executive Vice President, Chief Commercial Officer; and Andy Pasternak, Executive Vice President, Chief Strategy Officer.

Tim will provide a high-level review of our first quarter including an update on COVID-19, our TEPEZZA launch and guidance. Liz will then provide a review of our R&D programs followed by Paul, who will discuss our financial performance and guidance in more detail. After closing remarks from Tim, we'll take your questions.

Recommended For You

Comments (2)

I noticed that GENMAB did not include any guidance for Tepezza. This IMO could add nice value to GENMAB and Horizon.
While it is true that rapamycin is not commonly used in rheumatology practice, under the trade name Rapamune it is used by nephrologists to promote maintenance of renal transplants -- a potential target population for KRYSTEXXA. The fact that rapamycin is not fully effective in Selecta's SEL-212 is likely due to the much higher immunogenicity of Selecta's PEGylated uricase (pegadricase) compared with the pegloticase in KRYSTEXXA.
To report an error in this transcript, .Contact us to add your company to our coverage or use transcripts in your business. Learn more about Seeking Alpha transcripts here. Your feedback matters to us!

More on HZNP

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.